Q1 2022 earnings call transcript

AXA 1Q22 Activity Indicators

Transcript

May 6, 2022

GIE_AXA_Internal

DISCLAIMER

This document is the transcript of the 1Q22 Activity Indicators presentation to analysts and investors held on May 6,

2022. The webcast of this presentation is available on https://www.axa.com/en/investor/earnings-presentation. In the event of any inconsistency between the transcript and the podcast, the podcast will prevail. In addition, the following transcript is unedited, and statements and figures therein are accordingly in all cases subject to those set forth in AXA’s most recently published quarterly or annual results.

IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING

STATEMENTS AND THE USE OF NON-GAAP FINANCIAL MEASURES

Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations, or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed or implied in such forward looking statements. Please refer to Part 5 - “Risk Factors and Risk

Management” of AXA’s Universal Registration Document for the year ended December 31, 2021 (the “2021 Universal

Registration Document”) for a description of certain important factors, risks and uncertainties that may affect AXA’s business and/or results of operations. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events, or circumstances or otherwise, except as required by applicable laws and regulations.

In addition, this press release refers to certain non-GAAP financial measures, or alternative performance measures

(“APMs”), used by Management in analysing AXA’s operating trends, financial performance and financial position and providing investors with additional information that Management believes to be useful and relevant regarding

AXA’s results. These non-GAAP financial measures generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies. As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group’s consolidated financial statements and related notes prepared in accordance with IFRS. A reconciliation from the underlying earnings APM to the most directly reconcilable line item, subtotal or total in the financial statements of the corresponding period is provided on pages 49 and 50 of the 2021 Universal Registration Document. The above mentioned and other non-

GAAP financial measures used in this press release are defined in the Glossary set forth in Appendix V on pages 501 to 505 of AXA’s 2021 Universal Registration Document.

GIE_AXA_Internal Page 2 | 17

1Q22 ACTIVITY INDICATORS – CONFERENCE CALL TRANSCRIPT

Anu Venkataraman, Head of Investor Relations, AXA

Thank you, operator. Good morning, and welcome to AXA's conference call on our activity indicators for the first three months of 2022. Our Group CFO, Alban de Mailly Nesle, will take you briefly through last night's release. At the end of his introductory remarks, we'll be happy to take your questions.

Alban, I hand over to you.

Alban de Mailly Nesle, Group Chief Financial Officer, AXA

Thank you, Anu. Good morning to all of you and thank you for joining the call today.

So, as you saw from our release yesterday evening, AXA delivered a high-quality growth in the first three months of

2022. The performance across our technical and fee-based businesses has been excellent, in particular, Health, P&C

Commercial lines Insurance, Protection and Unit-Linked, all off to a strong start in 2022. At the same time, we have taken decisive underwriting actions to reduce Nat Cat exposure at AXA XL Reinsurance as previously communicated.

We are also maintaining a strong discipline in Life & Savings, shifting to a very high-quality mix and away from traditional General Account. Overall, our total revenues increased by 1%.

I am very pleased with the direction of travel as we are executing on our strategy, focusing on growing in our core technical segments.

Our balance sheet continues to be very strong with a Solvency II ratio at 224%.

Let me now go through the key numbers of the press release, starting with P&C. P&C revenues were up 2% overall, with growth in both Commercial and Personal lines.

Commercial lines insurance, which excludes AXA XL Re, had a strong start to the year, growing by +4%. We continue to benefit from favorable pricing conditions across all of our geographies. Growth was particularly strong in Europe and France, with revenues up 6% and 4%, respectively.

At AXA XL Insurance, pricing on renewals remained strong, increasing by +10% and well ahead of loss trends.

Revenues here were stable, with growth in Property and lower revenues in Casualty. This reflects our prudent approach to managing our exposures as we remain focused on profitability.

What you also see in our market is customers trying to optimize insurance purchase by agreeing to higher deductibles or lower limits in response to higher prices. This has also impacted exposure growth.

GIE_AXA_Internal Page 3 | 17

At AXA XL Reinsurance, we have reduced our Nat Cat exposure by ca.40%, in line with our strategy. The reduction will continue for the rest of the year as the business comes up for renewal. Overall, revenues in Reinsurance declined by 12% and this includes the impact of favorable pricing momentum that continued this quarter at +8%.

Now, on to Personal lines. The gross revenues were up +1% in the quarter. We are seeing excellent growth in Personal

Non-Motor at +5%, and this is driven in equal parts by volume and price across geographies, and the outlook is supportive. Personal Motor declined by -1%. Pricing, up 1%, is starting to respond to inflationary pressures. Volumes remained subdued in the first quarter, notably reflecting lower new car registrations.

We remain attentive to inflation and are being proactive in managing claims, including through procurement, partnerships and claims orientation. In addition, new ways of working have kept claims frequency below pre-COVID levels.

Now moving to other lines of business. In Health, revenues overall were up 6% in the first quarter, driven by higher volumes and better pricing. Both Individual and Group businesses reported strong growth momentum. France performed again extremely well this quarter with revenues up 8%, notably from the continued success of its international partnerships in the US. In Mexico, revenues were up 15%, reflecting the strong pricing actions we have taken to restore profitability, which was negatively impacted by COVID-19 claims.

Now moving on to Life & Savings. We continue to see a favorable business mix with strong revenue growth in Unit-

Linked and Protection, offset by lower G/A savings. We are seeing similar trends in net inflows.

A few highlights on our 1Q revenue performance. France continued to perform very well in Individual Savings with a record share of both Unit-Linked and Eurocroissance products at 63%, 20 points ahead of the market. Switzerland saw strong growth in Protection, +5%, driven by the Group Life semi-autonomous business. Our strategic transformation continues to bear fruit. Our Protection business in Asia also delivered very good results, +8%, notably in Japan and Hong Kong.

Finally, in Asset Management, AXA IM continued to deliver a strong commercial performance with Euro 9 billion of net inflows, notably Euro 5 billion from third-party clients. Our management fees were up 10%, benefiting from higher average assets under management and an improving business mix towards alternatives. This was offset by lower performance fees, which, as you know, tend to be lumpy by nature.

As you have seen in our press release, we are now including Architas in our Asset Management segment.

Moving on now to Solvency II. So, our Solvency II ratio was 224% at the end of March, an increase of 7 points from the end of last year. This improvement reflects notably 2 points from the positive operating return, net of accrued dividend, 3 additional points from the net positive impact from the changes in IBOR in some geographies and negative UFR impact, +2 points from net debt issuance, and -2 points from the Euro 0.5 billion share buyback. The impact from financial markets was +2 points, driven by +10 points from increase in interest rates. So, I know that in

GIE_AXA_Internal Page 4 | 17 periods of heightened volatility, assessing the impact of market movement can be complex to model from the outside.

Our disclosed sensitivities reflect accurately the impacts of market movements, but they are not linear for significant moves. There is some convexity embedded. We have provided in our release, estimated updated sensitivities to changes in interest rates. Our sensitivity to a 50bps change, +50bps change, is now +5 points versus +9 points previously. This clearly shows the effect of convexity. Similarly, sensitivity to a -50bps decrease in rate is now -8 points versus -14 points previously.

So, this favorable effect of higher rates was partly offset by the following. First, lower equity markets, -2 points; higher implied volatility, -3 points, reflecting the higher cost of options and guarantees offered to policyholders; and the effect from inflation of -4 points. This reflects the impact on the change in inflation expectation across the inflation swap curve. Please note that it’s different from CPI. To be clear, this is a pure Solvency II model effect. It does not factor any management actions that would be taken to mitigate the impact of inflation, notably through cost reduction measures or increased pricing.

So, overall, a very strong Solvency II ratio at 224%, up from year-end level. We are very pleased with the reduced sensitivity of our balance sheet to moves in interest rates.

And so, before moving on to the conclusion, I would like now to say a word on Ukraine. As a company with deep roots in Europe, AXA has been profoundly moved by the tragedy affecting the Ukrainian people. To date, reported claims from this crisis have been immaterial. Aviation and marine risks, which are written at AXA XL, are very complex, and we expect claims to take time to develop and almost certainly to be the subject of litigation.

Based on our current assessment and the current scope of the conflict, we believe that net underwriting losses, including political risks, will be akin to a midsized Nat Cat event. Overall, we still expect AXA XL to contribute to the

Group's earnings growth in 2022.

So, to conclude, a few takeaways to highlight. We are focusing on executing our strategy and it continues to produce good results across the Group. AXA performed very well this quarter with high-quality growth, notably across Health and P&C Commercial lines Insurance. We have a very attractive business profile focused on technical risks and cash generative lines. Our balance sheet remained strong with a Solvency II ratio of 224% and with lower sensitivity to interest rates. We completed our Euro 0.5 billion share buyback, and you can expect us to remain disciplined in the deployment of our excess cash resources.

So, the group is in a very strong position with a very good outlook. We are well placed in the current uncertain environment.

I'm now happy to take your questions.

GIE_AXA_Internal Page 5 | 17

Q&A SESSION

Operator And we have our first question from Andrew Sinclair from Bank of America. Please go ahead.

Andrew Sinclair | Bank of America Thank you. Good morning, everyone. Three for me, as usual. Firstly, just if you could let us know some context on what you actually see as a mid-sized Nat Cat?

And, secondly, I was just… speaking on Russia and Ukraine, what context can you give us on how you get comfortable with that level of net insured losses? And is it because of reinsurance protection, types of claims you feel will actually hit the industry and maybe how that relates to the cover you provide? Is it cancellation of policies in time? What gives you that level of comfort?

And, thirdly, it was just on Nat Cat actually, just I didn't see any comments on Nat Cat losses in Q1. Just any color you can give us there? I think you usually give a little bit of color in the quarter since owning XL. Thanks.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Hello, Andrew, and thank you for your questions.

So, I'll start by the third one on Nat Cat. We didn't mention anything on Nat Cat, because, obviously there were some natural events this quarter – you have in mind the Eunice and Franklin in Europe or the Australian floods, but there was no large Nat Cat that would be material to the Group.

So that's the perfect transition to your first question on what is a mid-sized Nat Cat. What we have in mind by saying that is that it's similar to the loss that we had last year with the Texas freeze, which is a Cat which is not material to the Group. And as you maybe heard in what I said, we still expect AXA XL to contribute to the Group's earnings' growth despite that loss on political risk, aviation and marine due to the Ukraine war.

So, on this, particularly, if you let me, I want to spend one minute to describe why it's complex. But complexity doesn't mean that the loss would grow indefinitely. We know our exposures. We know our reinsurance. It's just that the mechanisms that I'm going to describe are such that to put a precise number now would be difficult, but we will do that for H1, and we'll share with you then what is our best estimate of that cost.

So let me explain where we are on this. So, we have received very few claims to date, first. Second, our standard property policies typically contain exclusion for losses arising from war and other hostile acts. Now it's common, as you would know, that such losses would be included in coverages for political risk, aviation and marine. And in that regard, aviation is particularly complex. Aircraft and aircraft spare parts are covered by a metrics of policies taken out by different parties. And what I mean by this is, aircraft operators, aircraft lessors, manufacturers, financiers. And there are typically separate policies covering losses from war perils and for losses caused by non-war perils.

So, what happened? The sanctions declared by the UK and the EU on February 26th required aircraft lessors to cancel leases with Russian airlines. On March 14th, Russia passed a law that enabled Russian airlines to re- register foreign aircraft on the Russian Aircraft Registry. And, at this stage, it's unclear what effect that law might have on the ability of foreign aircraft owners to repossess or to retrieve aircraft from Russia and whether any re-

GIE_AXA_Internal Page 6 | 17 registration might constitute theft or confiscation or nationalization of seizures. So, we need to assess whether there's been a loss as well as how and when the losses were incurred. And, furthermore, we will need also to ascertain if lessors have taken action to mitigate the damages and what recoveries we may be able to get through salvage or subrogation.

So, you see the complexity and we expect that many of those issues will be subject to protracted litigation. It will take years to get to the final result. So, again, complexity doesn't mean that this can drift significantly. It just means that we need more data to come to a more precise number. Hence, it's not a ballpark figure, but a ballpark notion of a mid-sized Nat Cat event.

Andrew Sinclair | Bank of America Thanks, Alban.

Operator So, we have another question from Michael Huttner from Berenberg. Please go ahead.

Michael Huttner | Berenberg Fantastic. Thank you very much. I've got a fishing question. I hope you like it. So,

SCOR today, another French insurance or reinsurance Group, gave a figure for their IFRS 17 balance sheet including contractual service margin. I think the figure is Euro 9 billion. And I just wondered, what is your figure?

If SCOR have it, I'm sure you have it and I wondered, I'm sure it could be good opportunity to start discussing

IFRS 17. It's not that far away.

And my second question is on inflation and pricing. You made lots of different comments on inflation and pricing.

Some bits were good. Some bits you didn't talk about, so they're presumably not good. And I just wondered if you could kind of go back over it and give us a little bit more clarity? At the moment, I see that AXA XL is good. I'm not sure if the rest of Commercial lines is good or not, not clear for me. So maybe I'm not clear. And Personal lines, it sounds like there's a big lag, but maybe you can explain what's happening? That would be really, really helpful.

And then the final one is a really small one. What is solvency today? Thank you.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Sorry Michael, I didn’t hear the very last one. What is solvency?

Michael Huttner | Berenberg Solvency today, as of now.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA So, thank you for your questions. I see, I might disappoint you on the very first one, because we will give you more details on our IFRS 17 numbers in Q4, probably with the Q3 activity release, and you'll have the full numbers next year. So, sorry for that. On inflation…

Michael Huttner | Berenberg Can I just interrupt?

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Sure.

GIE_AXA_Internal Page 7 | 17

Michael Huttner | Berenberg I think you might think again. If SCOR can do it, there's no reason AXA can't do it.

And I imagine a lot of investors will be asking that question. So, my feeling is, you should accelerate that. Investors will welcome it. And if you don't, they might feel a little bit disappointed.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Okay. Point taken.

So, inflation and pricing, we need to be very precise on this and look at the different business lines in P&C. When you look at XL, you see that the market is very hard still, and we concentrate on our profitability and, therefore, we take business where we can have still significant price increases on renewals. And you saw that, we are +10% at AXA XL Insurance.

And if I compare that to loss trends, so loss trend is not exactly inflation, but I think it will give you a good illustration of where we are. Loss trends at AXA XL are around 5%. So, you see that there is still margin expansion at XL.

When now, I look at Europe, there are three different lines of business. I'll start with Commercial lines. And so, we do see some inflation in Commercial lines, notably obviously, in Property with construction materials. But as you saw, what we have been saying for a number of months now is that we have the ability to increase prices and that's what we've been doing in all our countries in Europe, where you see that Commercial lines prices are up by 4% in France and 2% to 4% in Europe. You will note that Switzerland, given the strength of their currency, has not had much inflation to date.

That's the same story for Retail Non-Motor where there again, we have pushed for price increases in all our geographies and there again Switzerland is, to some extent, an exception for the same reason. But so, we are pushing for price increases and, therefore, that's a good offset to inflation.

So, what's happening in Motor? Motor is slightly different, because there again, we do see some inflation, but first, we are able to take measures to offset part of that inflation. And when I say part, it's at least 50% of it, through better procurement, through orientation, through better fraud detection, so that allows us to reduce the impact of inflation.

And, very importantly, what we see is that the frequency that we have is lower than the 2019 frequency level. And we don't attribute that benefit to COVID-19, we attribute it to two things.

The first one is the fact that we have better quality cars. And the second one is that we believe that new ways of working or remote working, whatever you call it, has a positive impact as well because people use less their cars and, therefore, there are fewer accidents. And so, at this stage, and obviously we need to be prudent on this, but, at this stage, we don't see the need to significantly increase prices in Motor. And you see that we are up 1%. And for us, that's sufficient to maintain profitability, but we don't want to enter into price wars. And so, you've seen that from country to country, sometimes we have positive net new contracts and sometimes we have negative net new contracts, depending on the local context.

GIE_AXA_Internal Page 8 | 17

And then on your third question on where is solvency today. I think what I can tell you is, you have our new sensitivity on interest rates, and we are very happy that those sensitivities, +5%/ -8%, are lower than before, because there again it shows the lesser sensitivity of the Group to financial markets. And then you have the sensitivity to inflation, which is -4 points for +50 bps of inflation and the sensitivities to equities have not changed.

Michael Huttner | Berenberg Fantastic. That’s really clear. Thank you so much.

Operator So, we have another question from Peter Eliot from Kepler Cheuvreux. Please go ahead.

Peter Eliot | Kepler Cheuvreux Thank you very much. Three from me as well, please, if that’s alright.

And the first one is just a follow-up on Michael's question just now. I mean, that was interesting, Alban, what you said about you can offset it through better procurement and fraud detection. I mean, I guess just playing devil's advocate, it seems those are things possibly you ought to be doing in your day-to-day business anyway. So, I'm just wondering what's changed? How inflation has enabled you to do those things better? That was the first one.

Second one, on your disclosure on inflation, I found that very interesting. And, I guess, when I look at the factors that feed into the inflation swap curve, I'm interested in how closely you feel those are aligned with the actual drivers or risks to your business and, therefore, how appropriate a sensitivity that is? Would be grateful for any comments you have there.

And then the final thing, a third one, I was really interested in what's happening in Switzerland, very impressive growth in semi-autonomous products. You attributed that to your current strategy. But, I mean, I think that strategy has been going on for a few years. So, I'm just wondering if you could give us more detail on what's specifically driving that very strong year-on-year increase there? Thank you very much.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Thank you, Peter. So, you're absolutely right on your first question. It's not inflation that is leading us to be more efficient, it's those programs of orientations, procurement, et cetera, that we are further enhancing. But it's continuous progress that we've had over the years, but some are linked to technology. What I mean by this is, we use artificial intelligence to detect fraud. Some time ago, it was 5% of the cases that were detected through artificial intelligence. Now, it's 25%. So, you have to put in place those tools to have the benefit on fraud detection.

On orientation, what we see is, it takes some discussions with agents, with brokers to have them accept that their customers will not be able to go to any repair shops, and that is in everybody's benefit that we take control of that. So, all of this takes time. I'm just saying that we've been pushing this for some time, but we still have some way to go, because it takes a bit of time and because technology helps, and we still see some room for improvement in all those actions that will help us compensate partially or totally the inflation impact.

On the inflation yield curve and the impact on business. So, as I tried to say in my introductory message, the way the model is done, you take your costs, and you know that we project our costs over the life of our policies. What

GIE_AXA_Internal Page 9 | 17 we apply is that inflation swap curve, mechanically. So, it does not fully reflect our business in the sense that, as you know, we have a Euro 500 million cost reduction target for 2023 compared to 2019 and we ignore it for the purpose of projecting our cash flows. We just take inflation, whereas in real life, we are taking a number of actions to contain inflation and to stick to our Euro 500 million target. So, that's short-term.

Mid- and longer-term, so if we take a macroeconomic view, our view is that the Central Banks, notably the Fed, and we've seen the powerful action they took this week, and we believe the same on the ECB, so they will take actions to curb the inflation spike that we see today. So mid- to long-term, we believe that the inflation swap curve that we see and, obviously, it's not the current CPI, it's much lower, does reflect, more or less accurately, but does reflect what will be the inflation in the future, because I guess that no Central Banks will tolerate a high level of inflation. So, I think that makes economic sense mid- to longer-term.

On Switzerland, so we moved to a model where we don't have the savings component on our balance sheet, but we still offer two things that are separate.

One is Protection and we are very competitive on that business. And why are we competitive? I think, it's important to understand what the change in model implied for us. When we had savings on our balance sheet, there was some cross subsidy from Protection prices to the Savings business. And, therefore, Protection prices needed to be higher to offset for the Savings business, which was G/A with guaranteed rates which were high.

Now that we have a pure Protection business, we can have more competitive Protection prices while being very profitable. So, it makes much more economic sense.

And the second component of that is that we advise the foundations, so to be simple, the pension funds, on their asset allocation and we have a fee for that without taking a risk on our balance sheet. So that's a very powerful model and, as you see, a very competitive one.

Peter Eliot | Kepler Cheuvreux That's great. Thank you very much. Could I just come back on the second point?

I mean, if I just take, for example, you may have some non-Life reserves, which might be very exposed to medical cost inflation, for example. I'm just wondering to what extent, if at all, that is reflected in the model? I'm just thinking, you know, you're looking at core inflation swap curve, but the reality is that your business is more granular and exposed to certain things there. I don’t know if that’s clear.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Yeah, absolutely, that's perfectly clear. So, on this, what we are looking at is the inflation rate that is embedded in our reserves. And we are, as always, cautious on this, and we review reserves thoroughly twice a year and we make sure that the inflation embedded in those reserves is adequate. There are exactly, as you said, some businesses where there is a direct indexation on CPI.

And I'm thinking of, for instance, Workers' Comps annuities. On that one, the impact is mechanical and is not linked to inflation swap curve, but to real CPI. But those reserves and that risk are hedged through inflation- linked assets on the asset side.

Peter Eliot | Kepler Cheuvreux That’s very clear. Thank you very much.

GIE_AXA_Internal Page 10 | 17

Operator So, we have another question from William Hawkins from KBW. Please go ahead.

William Hawkins | KBW Hi, Alban. Thank you for taking my questions. For Ukraine and Russia, what is your aviation and marine sums insured compared with the figures that you gave as of political risk when we were talking at the full year stage? I appreciate everything you say about the outcome being uncertain, but presumably the sums insured are pretty straightforward. So, if you could help us on that, please?

Secondly, please, what was your insurance loss on the Texas Freeze last year? I don't know that number.

And then related to that, I mean, clearly, I understand you're being coy on this issue. But whatever the number is, whether it's Euro 200 million, Euro 300 million or Euro 400 million related to the Ukrainian tragedy, on the assumption that largely falls in XL, that's a very big hit against a consensus assumption of Euro 1.2 billion. And you've made a very clear statement that you're optimistic you can keep growing earnings, which is great. But what are the offsetting factors? Because, again, whatever that number for Ukraine seems to be, is a big number against this optimism that XL can grow earnings?

And then, lastly, please, I apologize if I missed this in your interaction with Michael, but the 2%-point impact from markets in your Solvency II ratio, could you just help me understand how that breaks down between available and required capital, even if it's just qualitative or directional, please?

Alban de Mailly Nesle | Group Chief Financial Officer, AXA So, I'll start with the...well, your first three questions are linked. So, I will answer them in one go, if it's okay. So, what we mean on Ukraine and Russia is that it is not material to the Group. And for XL, it is a hit. That's for sure, which is like the hit on Texas Freeze last year that didn't prevent XL from achieving the Euro 1.2 billion. And we said that XL would participate in the Group's earnings growth.

What are the other aspects that allow us to say that? We've been clear that we were focusing on profitability. You saw that we have a +10% price increase on Insurance, +8% on Reinsurance, loss trend is at +5%. And we have significantly reduced, and we will keep on reducing our Cat exposure at XL Re. We've done that by 40% in Q1, and we'll carry on with that. So, we have margin expansion on the attritional and we have less exposure to Cat than last year. That allows us to be confident, I mean everything else being equal, obviously. We need to see if there are very significant, sorry, significant cat losses in an abnormal year, you can never predict, but that would affect also our GI entities. It's not specific to XL.

And XL budget allows for a number of severe losses. Obviously, this one, which is a man-made large loss, was not predictable as such, but we have a budget for man-made losses and for Nat Cat. So that's embedded in XL numbers.

On the Texas Freeze, so it's true that we didn't give a specific number, because, as I said, it was not material at

Group level. When it's material and we showed it, we show the numbers, and that's what we had for Bernd last year, the floods that we had in Europe.

GIE_AXA_Internal Page 11 | 17

And on the exposures to aviation and marine in Russia and Ukraine, I believe all this needs to be discussed in detail and we'll do that at H1. I think what matters at this stage is the comments I made on the overall loss it could represent. There is, we have obviously the exposure, but we also have a significant reinsurance on aviation that will come into play as well.

William Hawkins | KBW Thank you. And just, sorry, the solvency question, please?

Alban de Mailly Nesle | Group Chief Financial Officer, AXA So, on this, we’ll come back to you, but it’s a mix of both. It’s both EOF and SCR.

William Hawkins | KBW Got it. Thank you, Alban.

Operator So, we have another question from Thomas Fossard from HSBC. Please go ahead.

Mr. Thomas Fossard, your line is open.

Thomas Fossard| HSBC Yeah. Can you hear me now? Yeah. Good morning, everyone. Sorry for that.

Just one last question for me related to AXA XL Insurance growth. Actually, the revenue is flat, which, I mean, adjusted for the price increase, implied volumes are still running down 8% at the present time. I think that last year, Alban, you were a bit more - a bit on the capability of the primary line - insurance lines to show a bit more growth, I mean, at least taking the benefit of the rate increases. So, you highlight in your press release that you're still pretty cautious on Casualty lines. But maybe you can tell us what the outlook in terms of revenues for primary and if we should expect growth to pick up? Or I mean if you've changed a bit your mind given the current environment regarding inflation and maybe pricing adequacies? Thank you.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Thank you, Thomas. Several things to have in mind when looking at XL insurance revenues, which I agree were flat. So, prices on renewals were up +10%. On new business, by nature, new business is less profitable than renewals, simply because, obviously, we know less of the business, simply because if it comes to us, it's probably also because the price of it by our competitors are too high. So, we need to be more cautious on new business than on renewals.

What you need to have in mind as well is that Q1 is very much Europe. In Europe, we are comfortable growing on the Property side and that's what we did. But on the Casualty side, I think we said at the end of last year that it needed a bit more rates to reach the level of profitability that we want, and that's Europe. And I wouldn't say the same about the US. So, we'll see along the year how both short-tail and long-tail lines will grow in the US.

And, last item, what we start seeing as well is that with price increases some customers start reducing their demand for coverage. And so, they want higher deductibles, for instance. And that also leads to a reduction in exposure and, therefore, a reduction in premiums. So, it's all this combined and notably, obviously, the price increase that leads to XL's revenues being flat in Q1.

GIE_AXA_Internal Page 12 | 17

Operator So, we have another question from Andrew Crean from Autonomous Research. Please go ahead.

Andrew Crean | Autonomous Good morning, Alban. Listen, can we get a bit more clarity around Nat Cat and man-made losses? I think that what we're trying to get to is, was the Nat Cat in the first quarter above or below your normal Cat load and, therefore, the Russian, the man-made Russian losses, do they come on top of a lower or an average level of Nat Cat? That's what we're really trying to get to and really, we're not interested in the size of the Texas Freeze other than to know in monetary terms, roughly speaking, what you are looking at for Russia, which I think is a fair question to ask.

Secondly, you said on new business that you're not writing new business for Russian-owned assets located in

Russia. But two questions on that. Are you writing renewals of Russian-owned assets located in Russia? And what about new and renewals of foreign-owned assets located in Russia, are you writing those?

And finally, a question on M&A. AXA hasn't done any acquisitions since 2018. I think at the full year, you indicated that you are more open to bolt-on acquisitions. Could you define what the maximum size of a bolt-on is?

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Thank you, Andrew, for your questions.

So, on Nat Cat, when I look at the Group overall, I would say that Q1 was broadly in line with what you would expect from a quarterly budget of Nat Cat and that our GI entities in Europe were more affected than XL, because

Eunice and Franklin were in Europe. So, I hope that answers your question.

On the Russian assets, so to be clear, we don't write, be it for new business nor for renewal, any policy on Russian assets on the Russian soil owned by Russians. Now if we have international programs for non-Russian companies with Russian assets, we, in the respect of sanctions obviously, cover their assets that are on the Russian soil.

And then on M&A, I think what we want to say by bolt-on doesn't really matter. What we mean is, it's acquisitions that are of a limited amount that will not come as a surprise and that are well embedded in the strategy that we have described to you where we want to use capital for both buybacks and acquisitions. So, it's not like it's a maximum amount, it is something that needs to make sense and is reasonably limited in size.

Andrew Crean | Autonomous And if you did an acquisition, how are we supposed to measure whether you would have got more benefit out of buying stock back?

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Yes. So, first, what we said was that we wanted to do acquisitions in countries and lines of business that makes sense for us. We don't want to put new flags on the map. And so, we gave the examples of countries where we want to be, such as Spain, Italy, Germany, which means that we will have synergies in those countries, because we are already present there. So, what we want to do when we compare to a share buyback is to look at the amount spent for the acquisition, see what would be the impact if we spend that amount for a buyback, and see, with the acquisition, taking into account the synergies and the moment they are realized, so say two or three years, how they compare to the benefit of the buyback.

GIE_AXA_Internal Page 13 | 17

Andrew Crean | Autonomous Thank you.

Operator So, we have another question from Ashik Musaddi from Morgan Stanley. Please go ahead.

Ashik Musaddi | Morgan Stanley Thank you, and good morning, Alban. Just one, a couple of questions actually.

One is, again, going back to this pricing and inflation, I mean, you gave very good clarity to Michael's question that you're able to offset the inflation through, say, other actions as well, but how should we read that into the combined ratio, especially from Europe? I mean, Europe, you have been hitting a combined ratio of around 92% for a reasonable time. So, would you say that that 92% is still safe, given that, I mean inflation is still running high but as you don't see that in the headline pricing at least what you're reporting both on Personal lines and on

Commercial lines in Europe? So that's the first one.

Second thing is Solvency II. When you mentioned the reduced sensitivity on interest rates, et cetera, I mean, how much of that is management action? And how much of that is just purely mechanics of convexity, et cetera? I think for volatility, you mentioned it's purely mechanics, but does that apply to interest rates as well? And given that your solvency ratio is high at about 224%, would you take some management actions to reduce that sensitivity, or would you say you are still happy with the exposure you have to interest rates? Thank you.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA So, on your first question, so I'll be disappointing you because in Q1, as you know, we don't comment on earnings. So, I will not comment on the combined ratio.

And I believe what I said on inflation and the way we manage to compensate it should give you some idea of where we stand.

On Solvency II, there is obviously some convexity, but convexity comes from our management. In other words, we have a duration gap. That duration gap was around 0.4 years three months ago in December, sorry, five months ago, and now it's closer to zero. But we have the ability to increase it or decrease it depending on where we want to be. So, we shouldn't believe that it's purely mechanical. At some point, we might want to say that we want to be more exposed to further rise in interest rates and, therefore, that we would want to increase our duration gap. That's not on the table today. We're very happy with the +5%/ -8% sensitivities that we have, but it's within the hands of management.

Ashik Musaddi| Morgan Stanley That’s very clear. Thank you. Thanks Alban.

Operator So, we have another question from Dominic O'Mahony from Exane. Please go ahead.

Dominic O'Mahony | Exane BNPParibas Hi. Good morning, and thanks for taking our questions. And If I could just firstly ask about back book transactions, interest rates have obviously moved north a lot over the past six months or so. Has that impacted your appetite to engage in back book transactions? Has that impacted the counterparty's appetite? Has it impacted the economics, or do you see those transactions that will lead to pricing? Any thoughts on that would be very helpful.

GIE_AXA_Internal Page 14 | 17

Similarly, on G/A savings, has the recent rates had any effect on your view of sort of the strategy that you've been pursuing for the last several years, of essentially trying to reduce your exposure there? Is there… at what sort of level would you start thinking again about whether that product might be attractive?

And then just on AXA XL, you said you expect it to contribute to the Group's earnings growth. Could you just help us understand what that means? Does that mean you think XL will grow its earnings or that it will be a contributor to earnings in general? I'm not sure quite how to read that statement. So, your help would be helpful.

And then the final question. Clearly, a very large reduction in Cat exposure in XL Re. I'm just wondering about the mix effect that has. Is the Cat business sort of higher or lower average combined ratio on a normalized basis? And so, what sort of net effect does that have on your sort of normalized combined ratio expectation? Thank you.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Let me write down all those questions. Okay. So, thank you, Dominic, for your questions.

On the first one, on the back book transactions, that hasn't changed the recent rise in interest rates. It has not changed our position and our appetite for several reasons. One is, we believe it's a strategy that makes sense because it reduces further our exposure to financial markets, and that's independent on the level of rates.

Second, we are still prudent on long-term rates. Obviously, they've gone up recently. It's not impossible that with interest rates hikes by central banks, a recession might come. And in such cases, it's possible, not obvious, but it's possible, that long-term rate yields would go down again. So, we need to be cautious in this current environment and we don't see any reason, sorry, to change our stance. Same for the buyers’ appetite. We have, as you know, a transaction going on and we don't see at all any reduction in their appetite to do those acquisitions of back books.

And so, it's a bit the same answer to your second question on G/A. We are, to be clear, we are not against G/A business. And when you look, for instance, at Eurocroissance in France, where we have guarantees at maturity, that's the kind of G/A business that we like and that we want to sell, because it's obviously better for us but it's also better for the customer, because it allows us to have a more dynamic asset allocation, because we don't have to be in line with our guarantees year after year, but only upon maturity. So that's the kind of G/A that we want to sell. What we don't like is the traditional one and that's why we are doing those in-force transactions.

On XL earnings, I said XL earnings growth, so we expect XL earnings to grow this year.

And finally, on the reduction in Nat Cat exposure and what impact it has on our normalized combined ratio. So, it's as you know, it is very specific to XL Re. We are not reducing our exposure to Nat Cat at XL Insurance or in our

GI entities in Europe. At XL Re, what we said, including last year, was that even with the price increases, we think that the Cat market is not yet adequately priced on the reinsurance side. So, it's not the only reason why we are reducing our Cat exposure, we believe it brings too much volatility. But, nevertheless, it gives you an idea of what we think about the profitability of the reinsurance Cat business.

GIE_AXA_Internal Page 15 | 17

Dominic O'Mahony | Exane BNPParibas Thank you very much. That’s really helpful, Alban.

Operator So, we have another question from Farooq Hanif from J.P. Morgan. Please go ahead.

Farooq Hanif | J.P. Morgan Hi everybody, and good morning. Just, firstly, on COVID-19 reserves. So, if I remember, in 2H 2021, the ability to release some of those reserves was a great benefit to get to your target. Can you tell us your latest thoughts there a few months on… (Technical Difficulty)

Anu Venkataraman | Head of Investor Relations, AXA Farooq, sorry, we’re having trouble - Farooq, we're having trouble hearing you. You keep breaking up. Would you mind just summarizing your questions for us again, please? We didn't catch the first one.

Farooq Hanif | J.P. Morgan Yes of course. So first one was COVID-19 reserves. Do you still have buffers there because I know that helped you in 2021? So, is that an area of padding that you could use?

Secondly, which areas of Casualty are you pulling out of and in which regions?

And, thirdly, political risk. Can you remind us of the numbers of sum assured that you told us and just update us on those numbers, net of reinsurance? Thank you.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Hello, Farooq. So, on COVID-19 reserves, so I'll remind you the numbers we gave at the end of last year. And so, we still had, within XL, 25% of IBNRs on COVID,

25% of the total loss. We will update you on this at H1. And on Casualty, if I understood your question, so it's

European Casualty that we have renewed at 1/1 and with some degree of prudence as I said earlier, but I want to make sure that I understood your question well.

And your third question, sorry, was it on…

Farooq Hanif | J.P. Morgan on political risk, so could you remind us the numbers?

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Yes. So, the total exposure was Euro 300 million for both Ukraine and Russia, and that was 50% quota shared. For the net, you have that amount.

Farooq Hanif | J.P. Morgan and on Casualty lines (Technical Difficulty)?

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Sorry, again, you’re breaking up. I’m very sorry,

Farooq.

Farooq Hanif | J.P. Morgan I’m really sorry. Which lines of Casualty are you pulling back from?

Alban de Mailly Nesle | Group Chief Financial Officer, AXA So, in Europe, you know the market is structured differently from the US. So, it's commercial casualty, but you don't have the same distinction as between the

GIE_AXA_Internal Page 16 | 17 primary, excess and so on, on this side of the ocean. So, the typical Group programs or company programs that we have in Europe that would be on products or environmental and general casualty. It's not specific. It's whether the prices make sense or not. But there's no specific line that is targeted.

Farooq Hanif | J.P. Morgan And just going back on the COVID-19 reserve, are you able or willing to give a number for how much of the initial reserves that you set aside, the Euro 1.5 billion, how much of that has been used?

Alban de Mailly Nesle | Group Chief Financial Officer, AXA So, no, the only number we mentioned is the Euro

1.5 billion that we had set aside and the Euro 400 million reserve release that we had at the end of last year. And, as I said, we'll update you on this in H1.

Farooq Hanif | J.P. Morgan Okay. Thank you very much.

Operator So, we have another question from Andrew Sinclair from Bank of America. Please go ahead.

Andrew Sinclair | Bank of America Just a couple more to follow up. And we've heard lots about underwriting losses from Russia, Ukraine, but I just really wondered if you could give us any color on asset exposures. I think you mentioned a Nordstream 1 investment amongst others. I just wondered if we could get an update there?

And secondly, just on your Reso stake. Any update there? Thanks.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA So, and I guess that will have to be the last questions.

On asset exposure, nothing has changed. What we said on February 24th was that we had less than Euro 50 million of exposure to Russia on the asset side and we have Euro 140 million of exposure to Nordstream 1 through a debt instrument. And there again, nothing has changed since then.

On the Reso, so there again, the only change is that we had two directors on the Reso's board and both directors have resigned. But apart from that, we still consider Reso as a financial participation. We don't have management control there and we have 38% of the company. So, nothing specific to report on that apart from the fact that the two directors resigned.

Andrew Sinclair | Bank of America Thank you very much.

Anu Venkataraman | Head of Investor Relations, AXA Well, thank you very much for your questions. If you have any further questions, please feel free to reach out to the Investor Relations team.

Alban de Mailly Nesle | Group Chief Financial Officer, AXA Thank you, all. Have a good day.

*** END OF THE TRANSCRIPT ***

GIE_AXA_Internal Page 17 | 17